Loading stock data…
PFE
$25.70+0.08 (+0.31%)
Market ClosedLast close Jun 9
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $25.79 with a market capitalization of $147.9B. Wall Street consensus targets $29.19 (27 analysts), implying a +13.2% move over the next 12 months. The stock is currently 10% below its 52-week high of $28.75, remaining 2.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHABBV
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$25.70
Potential Downside
26.7%
Whystock Fair Value$18.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$29.19+13.6%
Range$24.00 – $36.00
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$147.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.81
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Strong income play. Yield provides a meaningful total return floor.
663.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.31%
Volume
Today's trading volume
26.17M
Recent News
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
GSK Buys Nuvalent for $10.6 Billion in Major Cancer Push
(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’Stocks Hit by Chipmaker Rout Amid US-Iran Jitters: Markets WrapOpenAI Joins a Massive AI IPO Pipeline Now Worth $3.6 TrillionLA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump’
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.
Sciwind Reports 12.8% Weight Loss As Global Expansion Talks Deepen
New data showed ecnoglutide outperformed semaglutide in a China study of 163 patients.